S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.03%) $0.927
USD/NOK
(0.21%) $10.86
USD/GBP
(0.06%) $0.793
USD/RUB
(-0.34%) $92.26

Realtime updates for HLS THERAPEUTICS INC [HLS.TO]

Exchange: TSX Industry: Drug Manufacturersā€”Specialty & Generic
Last Updated28 Mar 2024 @ 15:59

10.50% $ 4.00

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 15:59):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally...

Stats
Today's Volume 8 600.00
Average Volume 9 024.00
Market Cap 127.69M
EPS $-0.170 ( 2024-03-14 )
Next earnings date ( $-0.250 ) 2024-05-08
Last Dividend $0.0500 ( 2023-04-27 )
Next Dividend $0 ( N/A )
P/E -3.45
ATR14 $0 (0.00%)

HLS THERAPEUTICS INC Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

HLS THERAPEUTICS INC Financials

Annual 2023
Revenue: $63.07M
Gross Profit: $55.45M (87.91 %)
EPS: $-0.850
Q4 2023
Revenue: $15.86M
Gross Profit: $13.33M (84.03 %)
EPS: $0
Q3 2023
Revenue: $16.04M
Gross Profit: $14.17M (88.34 %)
EPS: $-0.210
Q2 2023
Revenue: $16.42M
Gross Profit: $14.64M (89.18 %)
EPS: $-0.290

Financial Reports:

No articles found.

HLS THERAPEUTICS INC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.0500
(N/A)
$0.0500
(N/A)
$0.0500
(N/A)
$0.0500
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

HLS THERAPEUTICS INC Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.14 - low (4.63%) | Divividend Growth Potential Score: 2.41 - Decrease likely (51.72%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.0500 2019-01-30
Last Dividend $0.0500 2023-04-27
Next Dividend $0 N/A
Payout Date 2023-06-15
Next Payout Date N/A
# dividends 18 --
Total Paid Out $0.900 --
Avg. Dividend % Per Year 0.75% --
Score 2.81 --
Div. Sustainability Score 3.14
Div.Growth Potential Score 2.41
Div. Directional Score 2.78 --
Next Divdend (Est)
(2024-04-01)
$0.0509 Estimate 15.00 %
Dividend Stability
0.60 Above Average
Dividend Score
2.81
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2019 $0.200 1.43%
2020 $0.200 0.81%
2021 $0.200 1.18%
2022 $0.200 1.36%
2023 $0.100 0.99%
2024 $0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for TSX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
ZWC.TO Dividend King 2023-08-29 Monthly 8 4.07%
TRP.TO Dividend King 2023-09-28 Quarterly 30 3.81%
MFC.TO Dividend King 2023-08-22 Quarterly 25 3.24%
CUD.TO Dividend Knight 2023-09-25 Monthly 14 1.23%
XRE.TO Dividend King 2023-08-25 Monthly 23 2.24%
RCI-B.TO Dividend Knight 2023-09-07 Quarterly 25 1.93%
GEI.TO Dividend King 2023-09-28 Quarterly 13 3.90%
BASE.TO Dividend King 2023-08-30 Monthly 6 4.24%
VGV.TO Dividend Knight 2023-08-31 Monthly 7 1.42%
NBLY.TO Dividend Junior 2023-08-28 Quarterly 4 0.34%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.4361.500-8.73-10.00[0 - 0.5]
returnOnAssetsTTM-0.1321.200-4.39-5.27[0 - 0.3]
returnOnEquityTTM-0.2561.500-3.96-5.94[0.1 - 1]
payoutRatioTTM-0.0871-1.000-0.8710.871[0 - 1]
currentRatioTTM1.6520.8006.745.39[1 - 3]
quickRatioTTM1.2230.8007.516.01[0.8 - 2.5]
cashRatioTTM0.8231.5006.549.81[0.2 - 2]
debtRatioTTM0.419-1.5003.01-4.52[0 - 0.6]
interestCoverageTTM-1.1431.000-1.534-1.534[3 - 30]
operatingCashFlowPerShareTTM0.4892.009.8410.00[0 - 30]
freeCashFlowPerShareTTM0.4862.009.7610.00[0 - 20]
debtEquityRatioTTM0.897-1.5006.41-9.62[0 - 2.5]
grossProfitMarginTTM0.8791.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-0.1591.000-5.17-5.17[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1801.000-0.110-0.110[0.2 - 2]
assetTurnoverTTM0.3020.800-1.322-1.058[0.5 - 2]
Total Score3.14

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-3.471.000-0.4510[1 - 100]
returnOnEquityTTM-0.2562.50-2.54-5.94[0.1 - 1.5]
freeCashFlowPerShareTTM0.4862.009.8410.00[0 - 30]
dividendYielPercentageTTM1.6931.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM0.4892.009.8410.00[0 - 30]
payoutRatioTTM-0.08711.500-0.8710.871[0 - 1]
pegRatioTTM0.1021.500-2.660[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2501.0006.240[0.1 - 0.5]
Total Score2.41

HLS THERAPEUTICS INC

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators